The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Open accessAbstract
Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the α-subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitylation, and hence, proteasomal degradation, when oxygen is available. pVHL-defective clear cell renal carcinomas overproduce a variety of mRNAs that are under the control of HIF, including the mRNAs that encode vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor α. In preclinical models, down-regulation of HIF-α, especially HIF-2α, is both necessary and sufficient for renal tumor suppression by pVHL. These observations are probably relevant to the demonstrated clinical activity of vascular endothelial growth factor antagonists in clear cell renal carcinoma and form a foundation for the testing of additional agents that inhibit HIF, or HIF-responsive gene products, in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivation of the VHL tumor suppressor gene, which results in pseudo-hypoxic stabilization of both HIF-1α and HIF-2α, is an initiating genetic event for both hereditary (VHL disease) and sporadic ccRCCs [16].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although mTOR and the overall process of HIF-1α protein synthesis are limited under normoxia, it was found that 75% of sporadic clear cell RCCs are VHL-deficient, thus, in this case HIF-1α translation can proceed smoothly serving as a target for mTOR inhibitors intervention58.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation(2000) · PubMed · Cited by 1,445
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234
Cited by
Sorted by citations
Items 301–336 of 336
“Pseudoprogression”: more than semantics
Dutcher, J. P. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2208-y
Transcriptomic profiling of VHL-dependent long noncoding RNAs in clear cell renal cell carcinoma
Samuel, J. N., & Marsden, P. A. (2018) · European Urology Supplements · doi:10.1016/s1569-9056(18)33803-x
Canter, D. J., & Uzzo, R. G. (2011) · Springer eBooks · doi:10.1007/978-3-540-45021-4_31
Ko, J. S. (2009) · OhioLink ETD Center (Ohio Library and Information Network)
Prise en charge du cancer du rein métastatique
Dumont, C., Flippot, R., Bonnet, C., Gauthier, H., Albiges, L. K., & Culine, S. (2021)
Morbidelli, L., & Donnini, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00018-4
Von Hippel-Lindau Tumor Suppressor Gene
Decker, J., & Brauch, H. B. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_6218
Von Hippel-Lindau Tumor Suppressor Gene
Decker, J., & Brauch, H. B. (2017) · Springer eBooks · doi:10.1007/978-3-662-46875-3_6218
Von Hippel-Lindau Tumor Suppressor Gene
Decker, J., & Brauch, H. B. (2014) · Springer eBooks · doi:10.1007/978-3-642-27841-9_6218-4
Choueiri, T. K., & Golshayan, A. (2011) · doi:10.2217/ebo.11.13
Пили, Р., & Rodríguez, R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50090-7
Integrin-Linked Kinase (ILK) Expression as a Biomarker in Cancer of the Kidney
Engelman, M. D. F. B., & Engelman, G. G. (2016) · Springer eBooks · doi:10.1007/978-94-007-7699-9_46
PAS Proteins: Comparative Biology and Proteasomal Degradation
Pollenz, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64973-5
Yang, Y., Bai, J., Shen, R. Z., Brown, S. A. N., Komissarova, E., Huang, Y., Jiang, N., Alberts, G. F., Costa, M., Lu, L., et al. (2023) · doi:10.1158/0008-5472.c.6497244
Knaup, K. X., Jozefowski, K., Schmidt, R., Bernhardt, W. M., Weidemann, A., Jürgensen, J. S., Warnecke, C., Eckardt, K., & Wiesener, M. S. (2023) · doi:10.1158/1541-7786.c.6542193
Knaup, K. X., Jozefowski, K., Schmidt, R., Bernhardt, W. M., Weidemann, A., Jürgensen, J. S., Warnecke, C., Eckardt, K., & Wiesener, M. S. (2023) · doi:10.1158/1541-7786.c.6542193.v1
Combined Use of Cabozantinib and Nivolumab in Clinical Practice
Евгеньевич, А. В., Султанбаев, А. В., Меньшиков, К. В., Мусин, Ш. И., Султанбаева, Н. И., Popova, E. V., & Menshikovа, I. A. (2024) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2024-14-1-94-100
Screening of VHL mutation in different types of kidney cancer in patients of West Bengal (India)
Jalan, V., Yadav, R. P., Das, M., & Pal, D. K. (2023) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_48_22
Celada, L., Cubiella, T., Salerno, L., San‐Juan‐Guardado, J., Murías, E., Torres, M. D. S., Suárez‐Priede, Á., Weiner, J. A., Herrada‐Manchón, H., Fernández, M. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.26.609687
Kidneys, Adrenals, and Retroperitoneum
Katz, R. L., & Krishnamurthy, S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-5195-2.00028-5
PAS Proteins: Comparative Biology and Proteasomal Degradation
Pollenz, R. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.20004-1
Ragnoli, B., Pochetti, P., Chiazza, F., Bertelegni, C., Azzolina, D., & Malerba, M. (2025) · Advances in respiratory medicine · doi:10.3390/arm93060054
PAS Proteins: Comparative Biology and Proteasomal Degradation
Pollenz, R. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00208-6
Management of Renal Cell Carcinoma of Variant Histology
Zarrabi, K. K., Bilen, M. A., Tannir, N. M., & Barata, P. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-97599-8_18
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint
Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E., Andrianov, G. V., Childers, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.02.697373
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint
Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E. A., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305.1
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint
Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E. A., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305
Analyse comparative des carcinomes à cellules claires du rein et de leurs métastases
Dagher, J. (2018) · theses.fr (ABES) · doi:10.70675/695eba82zac17z4a9czaa88zca5d1d369dcb
Chung, H.-C., Hou, Y., Lu, K., Wang, C.-Y., Liao, C., & Wu, V. (2026) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj-d-25-00160
Bharti, N., Sureka, S. K., Singh, U. P., Gupta, O., & Rao, R. N. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-270527
Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer
Donninger, H., Ferrill, R., Hobbing, K., Vos, M., & Clark, G. J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1884868
Kopinski, P. K., Duffner, S. J., & Anguita, R. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102162
Renal cell carcinoma: molecular understanding and therapeutic development
Hou, T., Hua, X., Wei Min, N. I., Yan, P., Inuzuka, H., & Wei, W. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01857-9
Młynarska, E., Przybylak, A., Kurys, N., Krupińska, N., Pawlak, K., Witkowska, A., Rysz, J., & Franczyk, B. (2026) · Genes · doi:10.3390/genes17111340
Development of Combination Therapy with Targeted Agents
Cowey, C. L., & Hutson, T. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1622-1_17
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Clinical Cancer Research
- Published
- 2007-01-15
- Volume
- 13
- Issue
- 2
- Pages
- 680s-684s
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2131473358
- Semantic Scholar
- b1ecaaf13be1baca02f75edb325c7d80e991f9a6
- Cited by
- 336
- References
- 80
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 9 · 2019: 9 · 2018: 14 · 2017: 13 · 2016: 14 · 2015: 14 · 2014: 18 · 2013: 18 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- von Hippel-Lindau protein, VHL tumor suppressor, clear cell renal cell carcinoma, hypoxia-inducible factor, HIF-2α, HIF-1α, ubiquitin ligase, vascular endothelial growth factor, platelet-derived growth factor B, transforming growth factor-alpha, VEGF inhibitors, von Hippel-Lindau disease
- MeSH terms
- Carcinoma, Renal Cell, Genotype, Humans, Kidney Neoplasms, Mutation, RNA, Messenger, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Dimerization, Vascular Endothelial Growth Factor A, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
